Case Studies on Simcyp Simulator for Drug Development

This document is a collection of case studies detailing the use of the Simcyp Simulator in drug development, particularly for kinase inhibitor drugs. It outlines how the simulator has been utilized to replace clinical studies and inform pharmacology decision-making for over 40 novel kinase inhibitors approved by the US FDA in the past decade. The case studies include examples such as Imbruvica, Copiktra, Krazati, Kozelugo, and Scemblix, highlighting the simulator's role in predicting drug interactions, optimizing dosing strategies, and supporting regulatory approvals without the need for extensive clinical trials. Each case study presents specific outcomes, such as FDA acceptance of label claims based on PBPK modeling, demonstrating the technology's impact on drug development processes across various therapeutic areas, including oncology and rare diseases. The document emphasizes the increasing reliance on modeling and simulation in the pharmaceutical industry to streamline drug development and enhance patient safety.